Nanodelivery of Mycophenolate Mofetil to the Organ Improves Transplant Vasculopathy.

ABSTRACT: Inflammation occurring within the transplanted organ from the time of harvest is an important stimulus of early alloimmune reactivity and promotes chronic allograft rejection. Chronic immune-mediated injury remains the primary obstacle to the long-term success of organ transplantation. However, organ transplantation represents a rare clinical setting in which the organ is accessible ex vivo, providing an opportunity to use nanotechnology to deliver therapeutics directly to the graft. This approach facilitates the directed delivery of immunosuppressive agents (ISA) to target local pathogenic immune responses prior to the transplantation. Here, we have developed a system of direct delivery and sustained release of mycophenolate mofetil (MMF) to treat the donor organ prior to transplan

SUBMITTER: Uehara M 

PROVIDER: S-EPMC7247279 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature